sur Immunic AG
Immunic, Inc. to Announce Financial Results for Q2 2024 and Provide Corporate Update
NEW YORK, August 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company specializing in orally administered therapies for chronic inflammatory and autoimmune diseases, will disclose its financial results for the second quarter ended June 30, 2024, on August 8, 2024. The announcement will be made ahead of the U.S. financial markets opening, followed by a webcast at 8:00 am ET.
To join the webcast, participants are asked to register beforehand either via the provided Zoom link or through Immunic’s official website. A replay will be accessible approximately an hour post-event on the company's website.
Immunic is advancing several clinical programs, including vidofludimus calcium (IMU-838) and IMU-856, aimed at treating multiple sclerosis and gastrointestinal diseases respectively. Each program is progressing through various developmental phases, demonstrating promising results in preclinical and clinical trials.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Immunic AG